Arsenic Trioxide Prevents Osteosarcoma Growth by Inhibition of GLI Transcription via DNA Damage Accumulation

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Nakamura, Shunsuke ^a   Nagano, Satoshi ^a   Nagao, Hiroko ^a   Ishidou, Yasuhiro ^a   Yokouchi, Masahiro ^a   Abematsu, Masahiko ^a   Yamamoto, Takuya ^a   Komiya, Setsuro ^a   Setoguchi, Takao ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CISPLATIN; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN PATCHED 1; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; GL1 GENE; GL2 GENE; HEDGEHOG PATHWAY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PTCH1 GENE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA DAMAGE; HEDGEHOG PROTEINS; HUMANS; MICE; OSTEOSARCOMA; OXIDES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

ERINACEIDAE; MUS MUSCULUS;

EID: 84879966745     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069466     Document Type: Article

References (48)

1. Sweetnam R, (1982) Osteosarcoma. Br J Hosp Med 28112:: 116-121.
2. Dorfman HD, Czerniak B, (1995) Bone cancers. Cancer 75: 203-210. doi:10.1002/1097-0142(19950101)75:1+. PubMed: 8000997.
3. Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, et al. (2009) Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci 14: 397-404. doi:10.1007/s00776-009-1347-6. PubMed: 19662473.
4. Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, et al. (2006) Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 24: 1535-1541. doi:10.1200/JCO.2005.04.2978. PubMed: 16575004.
5. Ingham PW, McMahon AP, (2001) Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15: 3059-3087. doi:10.1101/gad.938601. PubMed: 11731473.
6. Ruiz i Altaba A, Sanchez P, Dahmane N, (2002) Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2: 361-372.
7. Lum L, Beachy PA, (2004) The Hedgehog response network: sensors, switches, and routers. Science 304: 1755-1759. doi:10.1126/science.1098020. PubMed: 15205520.
8. Ruiz i Altaba A, Mas C, Stecca B (2007) The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 17: 438-447.
9. Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, et al. (2011) Role of GLI2 in the growth of human osteosarcoma. J Pathol 224: 169-179. doi:10.1002/path.2880. PubMed: 21506130.
10. Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, et al. (2010) Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer 9: 5. doi:10.1186/1476-4598-9-5. PubMed: 20067614.
11. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, et al. (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297: 1559-1561. doi:10.1126/science.1073733. PubMed: 12202832.
12. Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, et al. (2003) Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci U S A 100: 4616-4621. doi:10.1073/pnas.0732813100. PubMed: 12679522.
13. Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, et al. (2009) GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 19: 5576-5581. doi:10.1016/j.bmcl.2009.08.049. PubMed: 19716296.
14. Tremblay MR, Lescarbeau A, Grogan MJ, Tan E, Lin G, et al. (2009) Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 52: 4400-4418. doi:10.1021/jm900305z. PubMed: 19522463.
15. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, et al. (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361: 1173-1178. doi:10.1056/NEJMoa0902903. PubMed: 19726761.
16. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, et al. (1998) Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391: 90-92. doi:10.1038/34201. PubMed: 9422511.
17. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, et al. (2000) Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406: 1005-1009. doi:10.1038/35023008. PubMed: 10984056.
18. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, et al. (2002) Mutations in SUFU predispose to medulloblastoma. Nat Genet 31: 306-310. doi:10.1038/ng916. PubMed: 12068298.
19. Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG, Toftgård R, et al. (2006) Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol 208: 17-25. doi:10.1002/path.1882. PubMed: 16294371.
20. Lee Y, Kawagoe R, Sasai K, Li Y, Russell HR, et al. (2007) Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 26: 6442-6447. doi:10.1038/sj.onc.1210467. PubMed: 17452975.
21. Sheng T, Li C, Zhang X, Chi S, He N, et al. (2004) Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 3: 29. doi:10.1186/1476-4598-3-29. PubMed: 15482598.
22. Lengfelder E, Hofmann WK, Nowak D, (2012) Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 26: 433-442. doi:10.1038/leu.2011.245. PubMed: 21904379.
23. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, et al. (2011) Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 121: 148-160. doi:10.1172/JCI42874. PubMed: 21183792.
24. Kim J, Aftab BT, Tang JY, Kim D, Lee AH, et al. (2013) Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23: 23-34. doi:10.1016/j.ccr.2012.11.017. PubMed: 23291299.
25. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA, (2010) Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A 107: 13432-13437. doi:10.1073/pnas.1006822107. PubMed: 20624968.
26. Plesca D, Crosby ME, Gupta D, Almasan A, (2007) E2F4 function in G2: maintaining G2-arrest to prevent mitotic entry with damaged DNA. Cell Cycle 6: 1147-1152. doi:10.4161/cc.6.10.4259. PubMed: 17507799.
27. Jung HS, Kim HS, Lee MJ, Shin HY, Ahn HS, et al. (2006) Arsenic trioxide concentration determines the fate of Ewing's sarcoma family tumors and neuroblastoma cells in vitro. FEBS Lett 580: 4969-4975. doi:10.1016/j.febslet.2006.07.077. PubMed: 16930595.
28. Mathieu J, Besançon F, (2006) Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells. Int J Cancer 119: 1723-1727. doi:10.1002/ijc.21970. PubMed: 16646077.
29. Yang W, Liu X, Choy E, Mankin H, Hornicek FJ, et al. (2012) Targeting hedgehog-GLI-2 pathway in osteosarcoma. J Orthop Res, 31: 502-9. PubMed: 22968906.
30. Bigelow RL, Chari NS, Unden AB, Spurgers KB, Lee S, et al. (2004) Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem 279: 1197-1205. PubMed: 14555646.
31. Regl G, Kasper M, Schnidar H, Eichberger T, Neill GW, et al. (2004) Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res 64: 7724-7731. doi:10.1158/0008-5472.CAN-04-1085. PubMed: 15520176.
32. Narita S, So A, Ettinger S, Hayashi N, Muramaki M, et al. (2008) GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res 14: 5769-5777. doi:10.1158/1078-0432.CCR-07-4282. PubMed: 18794086.
33. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, et al. (2011) ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30: 4874-4886. doi:10.1038/onc.2011.195. PubMed: 21625222.
34. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, et al. (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361: 1164-1172. doi:10.1056/NEJMoa0905360. PubMed: 19726763.
35. Bisht S, Brossart P, Maitra A, Feldmann G, (2010) Agents targeting the Hedgehog pathway for pancreatic cancer treatment. Curr Opin Investig Drugs 11: 1387-1398. PubMed: 21154121.
36. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA, (2002) Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A 99: 14071-14076. doi:10.1073/pnas.182542899. PubMed: 12391318.
37. Roberts WM, Douglass EC, Peiper SC, Houghton PJ, Look AT, (1989) Amplification of the gli gene in childhood sarcomas. Cancer Res 49: 5407-5413. PubMed: 2766305.
38. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, et al. (1993) Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53: 5535-5541. PubMed: 8221695.
39. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, et al. (2008) The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 27: 3282-3291. doi:10.1038/sj.onc.1210991. PubMed: 18084326.
40. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, et al. (2009) GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 284: 9074-9082. doi:10.1074/jbc.M806233200. PubMed: 19189974.
41. Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, et al. (2009) GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 23: 24-36. doi:10.1101/gad.1753809. PubMed: 19136624.
42. Xu Y, Chenna V, Hu C, Sun HX, Khan M, et al. (2011) Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 18: 1291-1302. PubMed: 21868763.
43. Pan D, Li Y, Li Z, Wang Y, Wang P, et al. (2012) Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin. Leuk Res 36: 742-748. doi:10.1016/j.leukres.2012.02.012. PubMed: 22398221.
44. Mazumdar T, Devecchio J, Agyeman A, Shi T, Houghton JA, (2011) Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res 71: 5904-5914. doi:10.1158/0008-5472.CAN-10-4173. PubMed: 21747117.
45. Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, et al. (2006) Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 66: 6763-6771. doi:10.1158/0008-5472.CAN-05-3699. PubMed: 16818652.
46. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, et al. (1996) The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15: 6269-6279. PubMed: 8947050.
47. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, et al. (2000) Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 275: 36062-36066. doi:10.1074/jbc.M007204200. PubMed: 10967126.
48. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, et al. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360. PubMed: 9129042.